How do the effectiveness and safety of long-acting GLP-1 RAs compare to short-acting GLP-1 RAs, when paired with basal insulin?
Read More »Low-Calorie Mediterranean Diet vs. Low Carb Diet for Weight Loss
Study examines the effect of Mediterranean or low carb diet on weight, waist circumference and blood glucose in patients with obesity.
Read More »Can Type 1 Diabetes Affect Reproductive Ability in Women?
According to new studies, women diagnosed with type 1 diabetes tend to have a shorter timeframe for reproduction than women without diabetes.
Read More »Overlooked Risk Factors for Type 2 Diabetes
Study identifies multiple risk factors for type 2 diabetes, including insomnia, that need to be incorporated into diabetes prevention strategies.
Read More »Fruit Consumption and Incidence of Type 2 Diabetes
Whole fruits, but not fruit juice, sustain insulin sensitivity and lessen the risk of type 2 diabetes.
Read More »The Risk Factor Responsible for Half of America’s Diabetes Cases
Approximately 30% to 53% of diabetes mellitus cases in the United States can be attributed to obesity.
Read More »HbA1c Changes as a Predictor of Cardiovascular Disease Incidence
HbA1c variability and swings between hypo- and hyperglycemia can increase risk of developing cardiovascular disease.
Read More »Adding Pramlintide to Artificial Pancreas Systems
The pancreas secretes both insulin and amylin, so should an artificial pancreas system provide insulin and pramlintide?
Read More »Doubling the Dose of Semaglutide for Weight Loss Approved
The new approval of Wegovy™ is for a current medication, semaglutide, but more than doubling the standard dose for diabetes treatment.
Read More »Tirzepatide Outperforms Insulin Glargine in HbA1c and Weight Loss
SURPASS-4 is a randomized controlled trial of tirzepatide once a week vs. insulin glargine once a day in type 2 diabetes patients with high cardiovascular risk.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.